Drug Trial Radar · NCT07589400
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of ACT500 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Complicated With Chronic Hepatitis B
Last checked: Nov 20, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Oct 30, 2026
Primary completion
Mar 30, 2027
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- Xiamen Amoytop Biotech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a Phase Ib, multicenter randomized, double-blind, dose-escalation, placebo-controlled trial designed to evaluate the safety, tolerability, PK, and PD profiles of multiple-dose ACT500 in participants with metabolic dysfunction-associated steatotic liver disease (MASLD) complicated with chronic hepatitis B (CHB). The trial plans to enroll 24 participants with MASLD complicated with CHB across three dose cohorts initially, each consisting of 8 participants who will receive oral ACT500 tablets once daily.
Conditions
- Metabolic Dysfunction-associated Steatotic Liver Disease
- Chronic Hepatitis b
Interventions
ACT500 TabletsDrug
Once daily, orally
ACT500 TabletsDrug
Once daily, orally
ACT500 TabletsDrug
Once daily, orally
ACT500 Placebo TabletsDrug
Once daily, orally
ACT500 Placebo TabletsDrug
Once daily, orally
ACT500 Placebo TabletsDrug
Once daily, orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse EventTime frame: Day1-112
- Serious Adverse EventTime frame: Day1-112
- body temperatureTime frame: Day1,14,29,56,84,112
- breatheTime frame: Day1,14,29,56,84,112
- pulseTime frame: Day1,14,29,56,84,112
- blood pressureTime frame: Day1,14,29,56,84,112
- Number of Participants with Abnormal Laboratory Parameters FindingsTime frame: Day1,14,29,56,84,112
- Number of participants with clinically significant change from baseline in physical examinationTime frame: Day1,14,29,56,84,112
- PR IntervalTime frame: Day14,29,56,84,112
- QRS IntervalTime frame: Day14,29,56,84,112
- QT IntervalTime frame: Day14,29,56,84,112
- QTc IntervalTime frame: Day14,29,56,84,112
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Beijing Friendship Hospital, Capital Medical University
Beijing, China
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, China
The First Affiliated Hospital of Xinjiang Medical University
Ürümqi, China
Xiamen Hospital of Traditional Chinese Medicine
Xiamen, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.